 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 June 1996 | Volume 124 Issue 12 | Pages 1058-1060
Objective: To define long-term outcome in patients with chronic hepatitis C who remain viremic after sustained biochemical response to interferon-
Design: Prospective evaluation of an outpatient cohort.
Setting: University hospital.
Patients: 107 patients with chronic hepatitis C who maintained normal aminotransferase levels as long as 12 months after interferon-
Measurements: Aminotransferase levels were monitored at 3-month intervals. Serum hepatitis C virus (HCV) RNA was tested by polymerase chain reaction before therapy, at the end of therapy, and 12 months after therapy. The HCV genotype was defined by spot hybridization using serum specimens obtained before treatment.
Results: Hepatitis C virus RNA was detected in 27 (25%) patients with sustained biochemical response; 80 (75%) patients were negative for HCV RNA. Patients positive for HCV RNA were older (P < 0.001), had received a smaller interferon-
Conclusion: Patients with chronic hepatitis C should be tested for serum HCV RNA 1 year after a sustained biochemical response to interferon-
Author and Article Information
The TriVeneto Viral Hepatitis Group
BRIEF COMMUNICATION
Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon-
in Chronic Hepatitis C
therapy. therapy. Patients were followed prospectively for an additional 6 to 36 months. dose (P = 0.02), and were more frequently infected with HCV genotype 2 (P < 0.01). Liver histologic findings were active in 57% of patients positive for HCV RNA, despite normal alanine aminotransferase levels, compared with only 12% of patients who were negative for HCV RNA (P = 0.01). The estimated probability of hepatitis relapse by 4 years after therapy was 53% in viremic patients and 0% in patients negative for HCV RNA (P < 0.001). therapy to determine whether the response is complete and permanent.
From the University of Padova, Padova, Italy; O.C. Pordenone, Pordenone, Italy; O. Le Grazie, Venezia, Italy; and O.C. Cittadella, Cittadella, Italy.
Grant Support: In part by grant 407/01/94 from Ricerca Sanitaria Finalizzata-Regione Veneto.
Requests for Reprints: Alfredo Alberti, MD, Clinica Medica 2, via Giustiniani 2, 35100 Padova, Italy.
Current Author Addresses: Drs. Chemello, Cavalletto, Casarin, Bonetti, Bernadinello, Pontisso, and Alberti: Clinica Medica 2, University of Padova, via Giustiniani 2, 35100 Padova, Italy. Dr. Donada: III Divisione Medica, O.C. Pordenone, via Monteverde, 33170 Pordenone, Italy.
This article has been cited by other articles:
|
|
 |
|
  Y. S. Khader, A. Dweek, A. Alkafajei, and A. Z. Rabi' Combination Therapy of Interferon and Ribavirin Versus Interferon Monotherapy in Treatment of Chronic Hepatitis C: A Meta-analysis of Clinical Trials Journal of Pharmacy Practice, October 1, 2006; 19(5): 265 - 274. [Abstract] [PDF]
|
|
|
|
 |
|
 P. b. H. Masur, J. E. Kaplan, and K. K. Holmes Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America Ann Intern Med, September 3, 2002; 137(5_Part_2): 435 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Walsh and G J M Alexander Update on chronic viral hepatitis Postgrad. Med. J., August 1, 2001; 77(910): 498 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shiratori, H. Yoshida, and M. Omata Effects of Interferon Therapy on Inhibition of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis C Jpn. J. Clin. Oncol., May 1, 2000; 30(5): 213 - 214. [Full Text] [PDF]
|
|
|
|
|
|
Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, O. Yokosuka, T. Kuroki, S. Nishiguchi, M. Sata, G. Yamada, et al. Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy Ann Intern Med, April 4, 2000; 132(7): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
USPHS/IDSA Prevention of Opportunistic Infections 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus Ann Intern Med, December 7, 1999; 131(11): 873 - 908. [Full Text] [PDF]
|
|
|
|
|
|
H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, M. Sata, O. Inoue, M. Yano, M. Tanaka, S. Fujiyama, et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan Ann Intern Med, August 3, 1999; 131(3): 174 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Pawlotsky, G. Germanidis, P.-O. Frainais, M. Bouvier, A. Soulier, M. Pellerin, and D. Dhumeaux Evolution of the Hepatitis C Virus Second Envelope Protein Hypervariable Region in Chronically Infected Patients Receiving Alpha Interferon Therapy J. Virol., August 1, 1999; 73(8): 6490 - 6499. [Abstract] [Full Text]
|
|
|
|
|
|
J.-M. Pawlotsky, G. Germanidis, A. U. Neumann, M. Pellerin, P.-O. Frainais, and D. Dhumeaux Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations J. Virol., April 1, 1998; 72(4): 2795 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hayashi, Y. Kishihara, K. Ueno, K. Yamaji, Y. Kawakami, N. Furusyo, Y. Sawayama, and S. Kashiwagi Age-Related Response to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection Arch Intern Med, January 26, 1998; 158(2): 177 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Hoofnagle and A. M. Di Bisceglie The Treatment of Chronic Viral Hepatitis N. Engl. J. Med., January 30, 1997; 336(5): 347 - 356. [Full Text] [PDF]
|
|
Article
